Potential Breakthrough Cystic Fibrosis Therapy in Phase 3 Trial

Jun 29, 2018 | Cystic Fibrosis

Cystic fibrosis, a genetic disorder impacting not only the lungs but also the pancreas, liver,kidneys and intestines.1 in 3000 may inherit cystic fibrosis in an autosomal recessive manner–originating from presence of mutations in both copies of the gene for the cystic fibrosis transmembrane conductance regulatory (CFTR) protein.

As reported in EurekaAlert! Children’s Hospital Colorado is participating in “one of of two Phase Three clinical trials related to the development of a possible breakthrough therapy for people with CF.” CHCs Mike McMorris Crystic Fibrosis Research and Care Center is one of the largest CF clinical care centers in the United States. Established in 1990, and accredited by the National Cystic Fibrosis Foundation, Their pediatric program cares for more than 400 children and adolescents with cystic fibrosis. Moreover approximately 300 people with cystic fibrosis are seen at the adult program based at National Jewish Health.

View article here

Source: Eurek Alert